# The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia

> **NCT05551221** · PHASE4 · RECRUITING · sponsor: **Xintian Pharmaceutical** · enrollment: 312 (estimated)

## Conditions studied

- Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms

## Interventions

- **DRUG:** Silodosin Capsules
- **DRUG:** Ningmitai capsule
- **DRUG:** Tamsulosin

## Key facts

- **NCT ID:** NCT05551221
- **Lead sponsor:** Xintian Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-18
- **Primary completion:** 2023-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2022-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05551221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05551221, "The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05551221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*